Haemonetics Corporation HAE
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.38B | 1.35B | 1.33B | 1.32B | 1.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.38B | 1.35B | 1.33B | 1.32B | 1.33B |
| Cost of Revenue | 557.58M | 553.23M | 544.53M | 527.88M | 543.22M |
| Gross Profit | 824.88M | 798.78M | 789.49M | 790.40M | 784.63M |
| SG&A Expenses | 463.33M | 447.61M | 441.05M | 431.39M | 431.21M |
| Depreciation & Amortization | 42.03M | 42.81M | 44.00M | 44.80M | 46.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.12B | 1.10B | 1.09B | 1.07B | 1.08B |
| Operating Income | 257.58M | 248.94M | 245.65M | 253.12M | 244.69M |
| Income Before Tax | 142.01M | 130.44M | 128.03M | 227.17M | 217.11M |
| Income Tax Expenses | 38.10M | 34.15M | 30.72M | 51.73M | 48.92M |
| Earnings from Continuing Operations | 103.91 | 96.29 | 97.31 | 175.44 | 168.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.91M | 96.29M | 97.31M | 175.44M | 168.19M |
| EBIT | 257.58M | 248.94M | 245.65M | 253.12M | 244.69M |
| EBITDA | 361.06M | 352.91M | 351.27M | 359.02M | 352.24M |
| EPS Basic | 2.27 | 2.06 | 2.04 | 3.65 | 3.44 |
| Normalized Basic EPS | 2.96 | 2.87 | 2.81 | 2.99 | 2.81 |
| EPS Diluted | 2.23 | 2.04 | 2.02 | 3.64 | 3.43 |
| Normalized Diluted EPS | 2.93 | 2.86 | 2.80 | 2.98 | 2.80 |
| Average Basic Shares Outstanding | 183.88M | 185.97M | 188.72M | 191.69M | 195.18M |
| Average Diluted Shares Outstanding | 185.38M | 186.58M | 189.23M | 192.48M | 196.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |